We are chemists, physicists, mathematicians, engineers, biologists who work alongside to design bionic units that mimic specific biological functions and/or introduce operations that do not exist in Nature. We apply a constructionist approach where we mimic biological complexity in the form of design principles to produce functional units from simple building blocks and their interactions. We called such an approach: Molecular Bionics.
We are engaged in several activities involving the synthesis and characterisation of novel hierarchal materials whose properties are the result of the holistic combination of its components:
We combine synthetic and supramolecular chemistry to tune inter/intramolecular interactions and self-assembly processes to form dynamic soft materials whose molecular, supramolecular and mesoscale structures are tuned and fit for the final application (pictured right: molecular engineering of nanoscopic structures starting from molecule passing to polymers and finally to supra molecular structures).
Our materials are designed to interact with living systems and thus its biological activity is studied in high detail. We have developed and established new methodologies to study living systems and how synthetic materials interact with them combining holistically physical and life sciences (Physical Biology).
Both know-hows are applied to study biological organisation and complexity creating synthetic surrogates that act as models, as well as to engineer novel sophisticated ways to interact with living organisms.
In analogy to medical bionics, where engineering and physical science converge to the design of replacement and/or enhancement of malfunctioning body parts, we take inspiration from viruses, trafficking vesicles and exosomes to apply molecular engineering to create nanoscopic carriers that can navigate the human body (Somanautics) with the final aim to improve drug delivery or create new diagnostic tools.
Visit our external website to find out more.
|CheSSTag · Chemotactic Super-Selective Targeting of Gliomas (2020-2023)||European Comission / ERC-CoG||G. Battaglia|
|BrainPePN · Nanomedicinas de precisión que penetran el cerebro (2021-2024)||MICIU / Retos investigación: Proyectos I+D||G. Battaglia|
|A por la COVID-19 (2021-2022)||IBEC / Faster Future 2020||G. Battaglia|
- State-of-the-art facilities for cell culture including 5 class A cell cabinets: one dedicated for LPS and RNAse free cell culture and one dedicated for infected tissues
- Fluorescence Activated Cell Sorting (FACS)
- Confocal microscope to perform live cell 4D imaging
- Real-time PCR
- Automated Western Blot
- Gel Permeation Chromatography
- High-Performance Liquid Chromatography
- Ultra Performance Liquid Chromatography equipped with fluorescence, UV/Vis and Infrared and light scattering detectors
- Dynamic light scattering unit
- Nanoparticle tracking analysis
- UV and Fluorescence spectroscopy
- Automated liquid handling units
- Nanoparticle production units
- Xavier Salvatella
- Francesca Peiro
Physics-University of Barcelona
- Kostas Kostarellos
Life Science- University of Manchester/ICN2
- Giorgio Volpe
- Simona Parrinello
Cancer Institute -UCL
- Finn Werner
Structural Biology -UCL
- Nick Lane
Evolutionary Biology -UCL
- Darren Hargraves
Pediatric Neuro-Oncology -UCL
- Timothy McHugh
Clinical Microbiology =UCL
- Sebastian Brander
- Joan Abbott
Physiology -King’s College London
- Molly Stevens
Bioengineering -Imperial College London
- Stefano Angioletti-Uberti
Materials Science -Imperial College London
- Ricardo Sapienza
Physics -Imperial College London
- Daan Frenkel
Chemisty-University of Cambridge
- Charlotte Williams
Chemistry -University of Oxford
- Francesco Gervasio
Pharmacology -University of Geneve/UCL, UK
- Francesco Stellacci
Bionegineering -EPFL Switzerland
- Tambet Tessalu
Cancer Biology -University of Tartu (Estonia)/ Sanford Burnham Prebys Medical Discovery Institute
- Darrel Irvine
- Xiaohe Tian
Life Sciences University of Anhui
- Yupeng Tian
Chemistry University of Anhui
- Lei Luo
Pharmacy -Southwest University, China
- Kai Luo
HuaXi hospital Sichuan University
- Darren Hargrave
Great Ormond Street Hospital, UCLH London
- Sebastian Brander
Queen Square National Centre for Neurology, UCLH London
Application Deadline: 30/06/2022Ref: LT_GB The Molecular Bionics group at the Institute for Bioengineering of Catalonia (IBEC) led by Prof. Giuseppe Battaglia at the Institute for Bioengineering of Catalonia (IBEC) is looking for a laboratory technician to support the animal research lines of the biology section of the team, as well as to contribute to the general lab maintenance.
Veronika Magdanz, of the Nano Intelligent Devices Group led by Samuel Sánchez, as well as Iris Batalha and Mohit Kumar of the Molecular Bionics group led by Giuseppe Battaglia, have … Read more
Last Friday, September 24, the “European Researchers’ Night” took place, an event that is held on a European scale in more than 300 cities in 30 different countries. The objective of this event is to publicize the diversity of science and its impact on the daily lives of citizens in a close and inspiring way. For yet another year, IBEC has not wanted to miss it and has been present at various activities.
Giuseppe Battaglia, leader of the IBEC “Molecular Bionics” group and ICREA Research Professor appears in various media for his recent study describing a mechanism and conditions that allow molecules to efficiently cross the blood-brain barrier, the protective layer of the brain.
The Institute for Bioengineering of Catalonia (IBEC) launches the Faster Future “A por la COVID19” campaign, with the aim of raising the 100.000€ needed to accelerate three research projects in collaboration with hospitals and patients associations.
An international study led by IBEC researcher Giuseppe Battaglia identifies a mechanism and conditions that allow molecules to efficiently cross the blood-brain barrier, the protective layer of the brain. This study describes the role of protein LRP1, bringing light to safe and efficient entrance of drugs to the brain.
In a new study published in the scientific journal Nature Communications, researchers describe a new concept called “range selectivity”, explaining why biomimetic nanoparticles only bind to receptors when their density is within a precise range. This finding could pave the way for the development of highly targeted therapies against a number of diseases.
An international team, led by Profs Giuseppe Battaglia and Loris Rizzello from the Institute for Bioengineering of Catalonia (IBEC), carried out out a study that opens the door to a new therapy capable of quickly and effectively eliminating infections caused by intracellular bacteria, the most resistant to immune defenses. This therapy, based on synthetic vesicles, could considerably reduce the dose and duration of antimicrobial treatments, thus reducing the danger of generating resistance to antibiotics of pathogens such as those leading to tuberculosis.
A team of international scientists led by the Institute for Bioengineering of Catalonia (IBEC) has developed a “faster, more effective and safer” therapy to eliminate infections of intracellular bacteria that cause diseases such as tuberculosis. Scientists participating in the study include Group Leader Giuseppe Battaglia and the researcher Loris Rizzello of IBEC.
Application Deadline: 17/10/2021Ref: PhD_IB The Molecular Bionics group at the Institute for Bioengineering of Catalonia (IBEC) is looking for PhD student to work on the development of targeted nanotherapeutics for drug delivery with a focus on infectious diseases and cancer. The project will be jointly supervised by Dr. Iris L. Batalha (La Caixa Junior Leader Fellow) and Prof. Giuseppe Battaglia. We are looking for a Chemistry/ Bioengineering/ Biotechnology graduate to work on an interdisciplinary project at the interface of chemistry and biology. The project will include the synthesis and functionalisation of polymers and assembly into nanoparticle delivery systems, protein expression and purification, generation of peptide ligands by phage display, and evaluation of targeted nanoparticles in vitro for applications in the treatment of infectious diseases and cancer.